For Scleroderma Research Studies, Worldwide Goes the Extra Mile

Scleroderma is a long-term progressive disease whereby the body produces an excess of collagen, resulting in thickening or hardening of connective tissue. Compared to other rheumatological conditions, sufferers of scleroderma tend to have higher rates of mortality and health complications. The heterogeneity of the disease necessitates precise stratification of patients according to subgroups for clinical assessment and treatment.

At Worldwide Clinical Trials, our scientific and medical professionals understand that the goals of IMID research focus on controlling inflammation, improving quality of life, and preventing tissue damage. We know that a sponsor’s good work realizes its full value once it can be applied in clinical practice to help the people who need it. Using innovation when traditional approaches don’t go far enough, the team at Worldwide is committed to achieving reliable data that holds up under regulatory scrutiny. Combining extensive expertise in trial design and execution with a personal commitment to your project goals, we are the CRO you can trust to optimize your chances for success. From Phase I-IV clinical trials to real-world evidence studies, count on Worldwide Clinical Trials.